FRIDAY, April 5, 2024 -- For patients with confirmed COVID-19, nirmatrelvir-ritonavir is not associated with a shorter time to sustained alleviation of symptoms than placebo, according to a study published in the April 4 issue of the New England Journal of Medicine.Jennifer Hammond, Ph.D., from Global Product Development at Pfizer in Collegeville, Pennsylvania, and colleagues randomly assigned adults with confirmed COVID-19 with symptom onset in the past five days to receive nirmatrelvir-ritonavir or placebo every 12 hours for five days (654 and 634 participants, respectively).

2024年4月5日，星期五——根据《新英格兰医学杂志》4月4日出版的一项研究，对于确诊为新型冠状病毒肺炎的患者，尼马曲韦-利托那韦与安慰剂相比，持续缓解症状的时间并不短。来自宾夕法尼亚州Collegeville辉瑞全球产品开发公司的Jennifer Hammond博士及其同事随机分配了过去五天内症状发作的确诊COVID-19的成年人，每12小时接受一次尼马曲韦-利托那韦或安慰剂治疗五天（分别为654名和634名参与者）。

From day 1 through day 28, participants logged the presence and severity of prespecified COVID-19 signs and symptoms daily.The researchers found that the median time to alleviation of all targeted signs and symptoms of COVID-19 was 12 and 13 days in the nirmatrelvir-ritonavir and placebo groups, respectively.

从第1天到第28天，参与者每天记录预先指定的COVID-19体征和症状的存在和严重程度。研究人员发现，尼马曲韦-利托那韦组和安慰剂组缓解COVID-19所有靶向体征和症状的中位时间分别为12天和13天。

Five and 10 participants in the nirmatrelvir-ritonavir and placebo groups, respectively, were hospitalized for COVID-19 or died from any cause (difference, −0.8 percentage points; 95 percent confidence interval, −2.0 to 0.4). The percentage of participants with adverse events was 25.8 and 24.1 percent for nirmatrelvir-ritonavir and placebo, respectively.'Nirmatrelvir-ritonavir was not associated with a significantly shorter time to sustained alleviation of COVID-19 symptoms than placebo, and the usefulness of nirmatrelvir-ritonavir in patients who are not at high risk for severe COVID-19 has not been established,' the authors write.The study was funded by Pfizer.Abstract/Full TextEditorialWhatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox..

尼马曲韦-利托那韦组和安慰剂组分别有5名和10名参与者因新型冠状病毒肺炎住院或因任何原因死亡（差异-0.8个百分点；95%置信区间-2.0至0.4）。尼马曲韦-利托那韦和安慰剂组不良事件发生率分别为25.8%和24.1%作者写道，与安慰剂相比，尼马曲韦-利托那韦与持续缓解COVID-19症状的时间没有显着缩短，尼马曲韦-利托那韦在严重COVID-19风险不高的患者中的有效性尚未确定。这项研究由辉瑞公司资助。摘要/全文编辑无论您感兴趣的主题是什么，请订阅我们的新闻稿，以便在收件箱中获得Drugs.com的最佳信息。。